Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia

NACompletedINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

May 31, 2017

Conditions
Community-acquired Pneumonia
Interventions
OTHER

the clinical reassessment arm

In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America

OTHER

the procalcitonin arm

In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.

Trial Locations (15)

Unknown

University hospital of Agen, Agen

University Hospital of Angers, Angers

University Hospital of Brest, Brest

University Hospital of Clermont-Ferrand, Clermont-Ferrand

University Hospital of Grenoble, Grenoble

CHD Vendée, La Roche-sur-Yon

University Hospital of Lille, Lille

CHU de Nantes, Nantes

University Hospital of Bichat Paris, Paris

University Hospital of Bobigny Paris, Paris

University Hospital of Hôtel-Dieu Paris, Paris

University Hospital of Saint Antoine Paris, Paris

University Hospital of Rennes, Rennes

University Hospital of Strasbourg, Strasbourg

University Hospital of Tours, Tours

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT01723644 - Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia | Biotech Hunter | Biotech Hunter